Neurofibromatosis type 1 (NF1) Program in Pharmaceutical Benefits Scheme (PBS) 012-24070423

This document outlines details of PBS-subsidised selumetinib for patients with neurofibromatosis type 1 (NF1).

NF1 and listing dates

NF1 is a genetic condition that causes tumours to grow along the nerves.

Listing date: selumetinib - 1 August 2024.

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs, and choose the option relevant to the condition treated.

The Resources page contains:

• application forms
• contact details
• restriction and item codes
• the PBS schedule
• Services Australia website link
• FAQs from Service Officers

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Written Authority Required Drugs

Processing Delayed Assessment requests in the Pharmaceutical Benefits Scheme (PBS)

Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)